References
- Nagata S., Goldstein P. The Fas death factor. Science 1995; 267: 1449–1456
- Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase‐mediated release of human Fas ligand. Journal of Experimental Medicine 1995; 182: 1777–1783
- Tanaka M., Suda X., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A. H., Nagata S. Fas ligand in human serum. Nature Medicine 1996; 2: 317–322
- Sato K., Kimura F., Nakamura Y., Murakami H., Yoshida M., Tanaka M., Nagata S., Kanatani Y., Wakimoto N., Nagata N., Motoyoshi K. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. British Journal of Haematology 1996; 94: 379–382
- Kanda Y., Tanaka Y., Shirakawa K., Yatomi T., Nakamura N., Kami M., Saito T., Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Chiba S., Yazaki Y., Hirai H. Increased soluble Fas‐ligand in sera of bone mmow transplant recipients with acute graft‐versus‐host di‐ sease. Bone Marrow Transplantation 1998; 22: 751–754
- Hahne M., Rimoldi D., Schrijter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J. C., Tschopp J. Melanoma cell expression of Fas (Apo‐1/CD95) ligand: Implications for tumor immune escape. Science 1996a; 274: 1363–1366
- Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apotosis induced by CD95 (Apo‐ Was) ligand‐expressing tumor cells ‐ A mechanism of immune evasion?. Nature Medicine 1996; 2: 1361–1366
- Xem L., Devilard E., Hassoun J., Haddad P., Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas‐mediated apoptosis. Leukemia 1997; 11: 1868–1877
- Tanaka M., Itai X., Adachi M., Nagata S. Down‐regulation of Fas ligand by shedding. Nature Medicine 1998; 4: 31–36